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In the autosomal dominant disorder epidermolytic hyperker-
atosis, the structural integrity of the keratin intermediate 
filaments is altered in the suprabasallayers of the epidermis. 
We and others have used genetic linkage studies and muta-
tion analysis to establish that single amino acid substitutions 
in either the keratin 1 or keratin 10 chains can cause epider-
moly tic hyperkeratosis. However, a larger database of muta-
tions is required to better understand the relationship be-
tween specific mutations in these keratin chains and their 
effect on keratin filament structure. A larger database will 
also provide a catalog that may be useful for genetic counsel-
ing purposes. In this paper, we report the identification of 
three new mutations of the keratin 1 chain of epidermolytic 
hyperkeratosis pro bands in highly conserved residues in the 
T he quantitatively major differentiation products of epidermal cells are the cytoskeletal keratin interme-diate filaments (KIF) . Normal human epidermis ex-presses two major type I/type II pairs of KIF chains: type II keratin 5 (K5) and type I K14 in the prolifera-
tive-potential basal cells, and type II Kl (and K2) and type I KlO in 
the suprabasal terminally differentiating epidermal cells. Together, 
these chains form the cytoplasmic KIF complement of these cells 
that in large measure is responsible for the physical properties of the 
entire epidermis [1,2] . 
Recent exciting molecular genetic and molecular biology experi-
ments have demonstrated that mutations in the KIF chains ex-
pressed in the epidermis are etiologically responsible for at least 
three distinct types of autosomal dominant genetic skin diseases, 
epidermolysis bullosa simplex (EllS), epidermolytic hyperkeratosis 
(EH), and palmar-plantar hyperkeratosis (reviewed in l3-7]). 
In EH, the integrity of the suprabasal layers of the epidermis is 
seriously disrupted, resulting in an altered differentiation program 
and highly abnormal, thickened stratum corneum [8,9J. Several 
types of data have now led to the understanding that the major 
underlying cause of this genetic disorder is mutation in either the 
Kl or KI0 chain. Cells of affected EH epidermis contain abnormal 
clumps of the KIF in the cytoplasm often found around the nucleus 
and near the cell periphery at desmosomal junctions [8 -1 0] . Using 
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H1 or beginning of the lA rod domain segments. These 
correspond to regions involved in molecular overlaps be-
tween neighboring molecules in keratin filaments . Using an 
in llitro assay, synthetic peptides bearing these substitutions 
show diminished capacity to disassemble preformed fila-
ments in lIitro in comparison to the wild type peptides. More-
over, analyses of all mutations in epidennolytic hyperkerato-
sis known to date demonstrate remarkable clustering in the 
molecular overlap region. We conclude that non-conserva-
tive substitutions in the overlap region are likely to interfere 
with normal keratin filament structure and function, leading 
to pathology. Key words: genodermatoses/ intennediate fila men ts/ 
epidermolysis bullosa simplex/epidermis. ] Inllest Dermatol 102: 
17-23, 1994 
this as an important clue to the disease etiology, our laboratory 
tested keratins, among other candidate genes, for linkage to EH in 
one large family, and found complete co-segregation of the disorder 
with the type II keratin gene locus on chromosome 12q [11 J. Be-
cause Kl is the major type II keratin expressed in suprabasal epider-
mis, we reasoned that a defect in this gene may underlie the pathol-
ogy. Indeed, sequence analyses of DNA obtained from all affected 
members of the family revealed a single point mutation in residue 
position 17 of the HI region of the keratin 1 gene that changed a 
CTT (leucine) to a CCT (proline), but not in any unaffected mem-
bers of the family [12]. Simultaneously, two other research groups 
reached the conclusion that defects in the Kl or KIO gene could 
cause EH. One of these employed transgenic technology using a 
chimeric gene construct bearing the likely promoter region of the 
KI0 gene and part of the KI0 coding sequences coupled to a dele-
tion form of the K14 coding sequences, to direct expression of the 
dominant-negative phenotype to the suprabasal layers of the epi-
dermis. Newborn transgenic mice displayed an abnormal epidermal 
phe. notype and changes in the supra basal layers reminiscent of the 
clinical features of EH in humans [13]; thus it was concluded that 
KI0 is a likely candidate for the disease etiology. Subsequent se-
quence analyses of DNA from affected patients of two occurrences 
of EH revealed the same arginine to histidine mutation at residue 
position 10 (RI0H) of the lA rod domain segment in the KI0 
protein [14]. A concurrent study by another group reported point 
mutations in either the Kl or 100 chain in three EH patients [15]: 
arginine to histidine at position 10 (R 1 OH) of the 1 A rod domain 
segment of KI0, leucine to serine at position 15 (U5S) of the lA 
rod domain segment of KI0, and glutamic acid to glutamine at 
position 118 (E118Q) of the 2ll rod domain segment of Kl. More 
recently, a mutation involving a leucine to proline substitution at 
position 6 (S6P) of the lA rod domain segment of Kl was found to 
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cause EH in another family [16] . Finally, linkage analyses in three 
other families have been reported in which the disease gene was 
mapped to the 12q region that contains the type II genes [17], 
thereby again implicating the K1 gene in disease etiology. 
Thus five different mutations that cause EH have been identified 
to date in either the Kl or KID chains. There are a number of 
important reasons it is necessary to generate a larger body of data on 
mutations that cause disease. First, for clinical diagnosis, it would be 
useful to determine whether there is a correlation between disease 
presentation and the type or location of mutation in either keratin 
chain. If indeed there are "hotspots" for mutations in the keratin 
chains as suggested [5,6], this would in turn facilitate identification 
of further mutations in the future simply because investigators will 
know where to look. Second, the creation of such a "catalog" of 
mutations will be of benefit for the future development of rational 
therapeutic approaches for the disease. Similarly, the availability of 
this information will be useful in genetic counseling of patients 
whose planned children are at risk of inheriting the disease-causing 
mutation. Additionally, an important spinoff may be a better under-
standing of KIF structure and function, which in turn may aid in 
diagnosis and treatment. 
To establish a catalog, we are in the process of analyzing the DNA 
from a large number of families with EH. In this paper, we report 
three new mutations in the K 1 chain resulting in amino acid substi-
tutions in different probands, and provide evidence that such substi-
tutions are likely to severely affect KIF structure and function ill 
I/i/ro, and by extrapolation, ill villo as well. 
MATERIALS AND METHODS 
Source of DNA DNA was isolated as described (1 8) from freshly drawn 
blood or transformed lymphocyte cel l lines obtained from both affected and 
unaffcctcd family mcmbers, as well as from additional unaffected unrelated 
persons. 
Direct PCR Atnpli6.cation of Keratin 1 Gene Exons Oligonucleo-
tide primcrs for amplification ofK1 exollS in fivc fragments, and primers for 
direct sequencing of these fragments are given below, based on the published 
human K1 gene sequence [12,19) . Some primers were as used in a previous 
study [1 2) and contained 5' sequences encod ing a restriction enzyme site 
(lowercase letcers) in addition co Kl specific sequences (uppercase letters); 
plus sign means sense strand and minus sign means antisensc strand. 
DNA Fragmellt I (Ineluding Exotl 1): Primer 1(+), located between the 
TATA box and the initiation codon (19), 5'-TGCTTGGGGTAGAG-
GAGTGTTTAGCTCCTTCCCTT. Primer GII(+), located in thc V1 
subdomain, 5'-TTTGGTGCTGGTGGTGGATTT. Primer J{+), also lo-
cated in Vl, 5'-TGGTTTTGGGGGTGGATATGGG. Primer 4n(-), lo-
cated in intron 1, 5'-TGCGTGTGTTTTGACTGCACCGAT. 
DNA Fragmellt II (Illeluding Exoll 2): Primer 5{+) in intron 1, (EcoRI), 
5' -ccggaattcTGGGGCACGGTTCTCCATGGCT ATGAGACTCC. 
Primer 6(-) in intron 2 (BamHI), 5'-gcgcggatccATAGTACATGCT-
GCTTCATGATCTTAGCTTATTAC.Primer6n{-)inintron 2,5'-TTA-
TT ACTTTTCTTGGAACTC. 
DNA Fragmfllt III (IlIellldillg Exolls 3,4,5, alld 6): Primer 6(+) in intron 2 
(EcoRI), 5' -gccggaattcAGCGAGT AAGCAGGCCAA T AA TGTTCCAA-
GGTTCA. Primer E4sp{+) in intron 3, 5' -CCCTCACAGGT AA TGAGA. 
Primer E5sp(+} in intron 4, 5'-GTTTTAGTGCTGTAAGAGTCA. 
Primer 10(-} in intron 6 (Bam HI), 5'-gcgcggatccGCACTCGCCCT-
TTACCTGTAGGGTTACCCCC. 
DNA Fragment IV (ltlellidillg Exoll 7): Primer 4411(+) in exon 6, 5'-
TCGACAATGTCAAGAAGCAG. Primer 108(+) in intron 6, 5'-
CTCACTGGAGTGGGGAGACCA. Primer 12(-} in intron 7. 5'-CAT-
CATTCGGTGGCAAGGAAGGAAGGACCA. Primer 2470(-) in exon 
8, 5' -GGGCACA TTCTCCAGACATC. 
DNA Fragllle/lt V (I/lcludillg ExotlS 8 alld 9): Primer 13(+) in intron 7 
(EcoRI): 5' -gccgaattcGTCTCCAAGATGGTGAAGCGGGGAATGGG-
GAAGCG. Primer 15(-) in the 3'-untranslatcd region (XbaI), 5'-ggctcta-
gaCGGT AAGGCTGGGACAAA TCGACCTCGGTCTTGCC. 
Primers for PASA assay: Primcr SPwt(-}: AACTCACCTTGTCAAT-
GAAGG~. Primer SPmut{-), AACTCACCTTGTCAATGAAGGQ. 
Conditions ofPCR About 400 ng of DNA was used per 100,u1 reaction 
with 1.5 mM MgClz, 200 ,uM dNTPs, a O.l,uM concentration of each of the 
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primcrs, and 2.5 units ofTaq polymerase (AmpliTaq, Perkin Elmer Cetus) . 
Amplifications were done on a DNA Thermal Cyclcr (Perkin-Elmer) for 35 
cycles (1, denaturation for 60 seconds at 94 ·C; 2, a 90-second transition to I 
55·C; 3, annealing for 30 seconds at 5S·C; 4, transition for 30 scconds to 
72 ·C; and 5, extension for 90 seconds at 72·C). Amplifications were pre-
ceded by a hot start: 5 -10 min incubation of the DNA and primer mix at 
95-100·C, and equilibration to 80-85 · C, at which time the premixed 
dNTPs, PCR buffer, MgClz' and Taq polymerase werc added and cycling 
started. To increasc the yield ofpCR product for direct sequencing, reampli-
fication was pcrformcd on a 1 : 100 to 1 : 1000 dil ution of the first amplifica-
tion rcaction. The primers uscd in the first PCR reactions were as follows: 
fragmcnt I, primcr 1 (+)/4n(-) or GII(+)/4n(-); fragment II, primcr 5(+)/ 
6(-); fragment III, primer 6(+)/10(-}; fragment IV, primer 4411(+)/ 
2470(-); and fragment V, primcr 13(+)/15(-) . The primers used in ream-
plification rcactions were as follows: fragment I, primer GII(+}/4n(-); 
fragment II, primcr 5(+)/6(-); fragment Ill, primer 6{+)/10(-); fragmenr 
IV, primcr 108(+)/2470(-); and fragment V, primer 13(+)/15(-). The 
amplified DNA fragments were resolved on 1.5% agarose gels and purified 
by the GeneClean II procedure (Bio 101) or by the Magic PCR Preps DNA 
purification system (Promega). 
Sequencing Procedures Direct scquencing of the PCR-amplified DNA 
was done in reactions using the single-strand binding protein (US Biochcm-
icals) to prevent strand reassociation [20). A 1 : 8 dilution of the labeling mix 
and about 300-500 ng of gel-purified DNA fragment were used for each 
direct sequencing reaction with the Sequenase 11 kit (US Biochemicals). 
Standard 6% denaturing polyacrylamidc gels wcre run. The primers used in 
direct sequencing reactions were as follows: exon 1, primer J(+)/4n(-); 
exon 2, primer 5(+)/6n(-); exon 3, primer 6(+}; exon 4, primer E4sp(+}; 
exon 5, primer E5sp(+); exon 6, primer 10{-); cxon 7, primer 108{+)/ 
12(-); and exons 8 and 9, primer 13(+)/15(-). These primers permitted 
analysis of most of the sequence ofKl , except for the variable Vl and V2 end 
domain regions. 
Screening Assays for Kl Mutations We developed assays that did not 
require DNA sequcncing to facilitate the dctection of each identified muta-
tion in patients and to screen for the occurrence of that mutation in the 
normal population. The V11 G substitution of family 1027 rcsults in the loss 
of a Mae III restriction enzyme site in DNA amplified from ex on 1 using 
primcrs GII(+) and 4n(-). Completed peR reactions (50 ,ul) were adjusted 
as recommended by Boehringer-Mannheim Biochemicals with NaCl, 
MgClz, and Tris-HCl and digested with 2 units of Mae III for 2-4 h, and 
analyzed on 3% agarose gels (NuSieve 3: 1, FMC Corp.). The N8S substitu-
tion in family 1002 results in the creation of a new Ode I site. The altered 
Ode I cleavage pattern was examined as above, exccpt that 2 units of enzyme 
were added directly to the completed PCR reaction. For the S13P substitu-
tion in family 3138, a PCR amplification of specific alleles (PAS A} assay was 
developcd [21 ). In this assay, PCR amplification is obtained specifically from 
the wildtype or the mutant allele using primers that differ only at the 3' most 
nucleotidc (sec primers listed above). The primers SPwt(-), speci fic for the 
wildtypc base T, and SPmut(-) speci fi c for the mutation C, were each used 
with GII(+) as the second primer. Amplifications were performed with 0.1 
mM dNTP, 1.5 mM MgClz' 120 ng DNA, and O.l,uM primers in 25,ul for 
30 cycles of 60-second denacuration at 95 ·C, 60-second annealing at 55 · C, 
and 60-sccond extension at 72 · C. 
Linkage Analysis Linkage analysis in family 1027 was performed using 
the computer program LINKAGE, subprogram MLINK on a 386 personal 
computer [12). EH was modeled as a fully penetrant disorder with allele 
frequency of 0.001. Analysis was robust over a range of disease and marker 
allele frequencies as all individuals included in the analysis were genotyped. 
Synthetic Peptides The following peptides, based on published se-
quences of human K10 [22) and mouse and human K1 [231 chains, were 
synthesized and purified by high-pressure liquid chromatography, and their 
compositions confirmed and concentrations ascertained by amino acid anal-
ysis: 1} wildtype Kl Hl, 1-36, PVCSPGGIQEVTINQSLLQPLNVEID-
PEIQKVKSRE; 2) mutant K1 H1, VllG, PVCSPGGIQEQTINQS-
LLQPLNVEIDPEIQKVKSRE; 3) wildtype Kl lA, REQIKSLNNQ-
FASFIDKVRFMEQQNKVLQTKWELL; 4) wildtype K1 lA, 1-18, 
REQIKSLNNQFASFIDKV; 5) wildtype Kl lA. 18 -35, VRFLEQQN-
KVLQTKWELL; 6} mutant K1 lA. N8S, REQIKSL~NQFASFIDKV; 7) 
mutant K11A, S13P, REQIKSLNNQFA!:FIDKV. 
KIF Disassembly Assay In Vitro Human KIF containing the Kl/K5/ 
KI0/K14 chains were prepared from frcshly excised foreskin epidermis as 
described previously [24), and cquilibrated into a buffer of 5 mM Tris-HCl 
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(pH 7.6) containing 1 mM ethylenediaminetetraacetic acid and 1 mM di-
thiothreitol. Peptides were dissolved in the buffer at 3 mg/ ml immediately 
before use, and added in 3 ILl aliquots to 0.25 ml of KIF so as to effect a 
twofold molar excess of peptide over KIF heterodimer (110 kDa) . At molar 
ratios exceeding about 2: 1, peptides 1- 3 began to aggregate the KIF in-
stead, apparently due to an ionic zipper effect [25]. Changes in tu rbidity were 
monitored by measuring .light scattering at 310 nm in a Beckman DU-65 
spectrophotometer at 37"C for 60 min [12,24,25]. We have determined 
empirically by electron mIcroscopy [11 ,25] that for KIF 2- 5 ILm 111 length, 
turbidity due to lIght scatter111g IS approxImately proportIonal to the square 
of KIF length; that is, minor changes in KIF length wi ll result in signifi-
cantly reduced turbidity. 
RESULTS 
During the course of the analysis of several EH families, we have 
discovered three hitherto undescribed mutations in the K1 gene that 
are the likel y cause of the disease. 
Clinical Description of Patients The diagnosis ofEH was con-
firmed by histopathology from skin biopsy specimens obtained 
from at least one affected person of each family. Patients in family 
I027 had primarily palmar and plantar involvement and truncal 
sparing . There was thick hyperkeratosis of the palms and soles, with 
a relatively smooth surface and sharp border delineated by a red 
halo. In some patients, there was restriction of full extension of the 
palms and di~its. Blistering from trauma ?r irritati~n (such as re-
strictive cloth1l1g) was reported, although It was a mIld component 
of the disease and tended to decrease with age. C hildren had som e 
generalized involvement, particularly of the fl exures and scaling at 
the corner of the lips, all of which improved over time. Patients 
IDD2 and 3138 had severe palmar-plantar hyperkeratosis with con-
tractures of the pa.lms and digits . One pat~ent had surgical amputa-
tions of rwo digits secondary to I11fectlOn. Both patIents were 
erythrodermic and had generalized hyperkeratosis, most severe over 
the joints, both fl exor and extensor surfaces. Inter-articular areas 
and most of the trunk were covered with fine white scale. The 
analysis and confirmation of these mutations are set forth below by 
family . 
The 1027 Family This is a three-generation family with six af-
fected individuals (Fig la) . Linkage analyses with the polymorphic 
markers developed in the V2 glycine loop sequences ofKl and KID 
described previously [11,26 ,27] documented an obligatory recom-
bination berween the disease phenotype and the K1D locus at 17q 
(denoted by asterisk in Fig 1a) . This excluded the possibility that a 
defect in K10 accounted for the disease in this family. The KRTI 
(K1) gene, however, was fully informative and showed complete 
cosegregation with a maximum lod score of 2. 1 at e = O. Direct 
sequencing of all exons of the K1 gene (except the V1 and V2 
regions of exom 1 and 9, respectively) in an affected individual 
amplified by PCR revealed heterogeneity at a single base position in 
exon 1 GGC in one Kl allele and GTC in the other allele. This 
leads to a substitution of valine for glycine in residue position 11 of 
the HI domain (VII G) (Fig 1 b). DNA amplified from exon 1 of an 
unaffected individual did not show the same change. We then de-
vised a tes t for the presence of this point mutation throughout the 
pedigree and in the normal control population. The T to G substitu-
tion destroys a restriction enzyme recognition site for M ae III 
(GTNAC) in the disease alle le. The PCR product of exon 1 is 497 
bp long, which for normal all.eles is cleaved by M ae III into frag-
ments of 297, 107, and 93 bp (Fig 1 c). However, the loss of the site 
due to the mutation gives a composite fragment of 390 bp (297 + 
93) from the disease allele, as well as the fragm en ts expected from 
the normal allele. Thus individuals heterozygous for this mutation 
w ill display four bands upon Mae III digestion (Fi g Id) . U sing the 
appearance of the composite 390-bp band as the assay, we docu-
mented that all affected members of this family possessed the mu-
tant allele, but only the normal allele was present in the eight unaf-
KERATIN 1 MUTATIONS IN EPIDERMOLYTIC HYPERKERATOSIS 19 
A 
B 
c 
III 
1 - 3 
1 - 1 
NO 
NO 
2-3 
I-I 
2-3 2-3 NO 
I - I I - I NO 
11 - 1 11- 3 
(EH) (unaffected) 
CTAGC T A G 
_497 
_390 
_297 
_107 
_93 
Figure 1. A valine to glycine mutation in family 1027. A) Pedigree of three 
generation fa mily. Below each person is indicated the genotype with respect 
to the polymorphic markers used for either the Ki0 (KRT10) or K1 (KRT1) 
loc i. For example, person 1-1 has size alleles 1 and 3 at the KRT I0 locus, and 
the 1 and 2 size alleles at the KRTl locus. These polymorph isms are due to 
variable numbers of glycine loops in the V2 subdomain regions of the K1 and 
KI0 genes [26,27]. By following the co-segregation of alleles through the 
family, it can be seen that in person 11-4 (asterisk), there is an obligate 
recombination between the disease locus and the KRT1 0 locus: she inherited 
the KRTI0-3 allele from her affected fath er, whereas her affected sibs in-
herited the KRTlO-I allele and her unaffected sib inherited the KRTlO-3 
allele. On the other hand, there is complete cosegregation with the KRT1 
(Kl) locus, with all affected individuals inheriting the KRTI-2 allele fro m 
1-1, whereas none of the alfecteds did. Individuals III-2 and III-6 were not 
tested (ND) as they were under 1 year of age, although they clea rly had the 
EH phenotype. B) Portion of a sequencing gel of an affected (left set oJlnt/es) 
and unaffected (right set oj Inl/es) family member, which shows an additional 
band in the G position, representing a nucleotide substitution in one allele 
resulting in a valine to glycine change. C) This mutation causes the loss of a 
Mae III restriction el12yme site in affected persons. I n the PCR product used 
for this work, affected persons possess a novel composite 390 bp band, which 
is used here to demonstrate that all unaffected persons of the fami ly and 
unrelated unaffected persons do not carry this substitution. Markers are 
123-bp ladder (Gibco-BRL). 
20 YANG ET AL 
A 2 
I I 
B 
(( - ( ( - 1 
(EH) unaffected 
parent 
[~\ C T A G C T A G K 
S [~ 
L [~ 
N ~ S [~/G~ 
N [~/ 
Q [~ 
A 
fee ted family members and in 53 unrelated unaffected individuals (a 
tota l of 106 alleles). 
The 1002 Family This family consisted of a single affected indi-
vidual and her two normal parents (Fig 2a). We amplified exons 1, 
2, 5, and 7 of the Kl gene, which encode virtually the entire rod 
domain including the Hl, lA, L12, and 2B segments. By direct 
sequencing, we found a single nucleotide substitution in one allele 
in residue position 8 of the lA rod domain segment (AAC to AGC, 
asparagine to serine) (N8S) in the affected child II-I (Fig 2b). DNA 
from both unaffected parents did not show this mutation (only 
parent 1-1 is shown) . This nucleotide substitution creates a Dde I 
restriction enzyme si te (CTNAG), which was then used as a tes t for 
the presence of the mutation in PCR-amplified DNA. In this analy-
sis, the normal alleles yield Dde I fragments of 347 and 150 bp, but 
the affected allele yields fragments of347, 103 (Fig 2c), and 47 bp. 
Because neither of the unaffected parents displays the new Dde I 
fragme nts, the A to G substitution in the affected child represents a 
new mutation. Similarly, 50 other normal unrelated individuals also 
lacked th e fragments of 103 and 47 bp. 
The 3138 Family This family also consisted of a single affected 
child and two normal parents (Fig 3a). Direct sequence analyses of 
D NA amplified from exons 1,2,5, and 7 from the affected individ-
ua11l-1 identified a single nucleotide substitution in one allele ofKl 
at position 13 of the 1 A rod domain segment (TCC to CCC, serine 
to proline) (S13P) (Fig 3b). N either of the parents showed this 
change. T his was confirmed as a new mutation as both Kl alleles 
fro m the parents showed only the T at this position (only parent 1-1 
is shown). T he nucleotide substitution removes an Mnl I restriction 
enzyme recognition site, but because there are several Mnl I sites in 
the peR product of exon 1 util ized in this work, the pattern was too 
complex for use. Therefore, a PASA assay was used to selectively 
amplify the w ildtype all ele or th e allele cartying the mutation (see 
c 
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Figure 2. An asparagine to serine mutation in family 1002. A) Pedigree of 
simplex family . B) Portion of a sequencing gel of the affected person (II-l ) 
(left scI of latles) and unaffected father 1-1 (right set of lal/es). The gel of the 
unaffected mother 1-2 was the same as 1-1 . The patient lI- l shows an addi-
tional band in the G position in one allele resulting in an asparagine to serine 
mutation. C) This mutation creates a new Ddel restriction enzyme site in the 
affected person. In the pe R product used here, the appearance of a 103-bp 
band is diagnostic for the affected person of the fa mily. Markers are 1 23-bp 
ladder. 
Materials and Methods). Only the affected individual gave a PCR 
product with both the mutant and wildtype-specific primers, 
whereas both unaffected parents were negative w ith the primer 
bearing th e mutation (Fig 3c). T he PCR product for the mutant 
allele was not detected in 47 unrel ated unaffected individuals using 
the mutated primer. 
Additional Nucleotide Sequence Variations in the Kl Gene 
During the course of sequencing nllInerous normal Kl all eles in this 
study, we found three hitherto undescribed single nucl eotide se-
quence variations. None of these segregate with EH suggesting they 
represent functionally equivalent alleles in the normal human pop-
ulation. Two silent codon variants were in the 2B rod domain seg-
ment, one at lysine 66 (codons AAA or AAG, estimated allele fre-
quencies of 0.95 and 0.05 , respectively), and the other at arginine 91 
(CGT or CGC, estimated allele frequencies of 0.5 each) . The third 
nucleotide variation is in the second position of codon 11 of the E2 
end domain segment (AAG lysine or AGG arginine, estimated allele 
frequ ency of 0.75 and 0.25, respectively). 
Use of Synthetic Peptides in Functional Assays for Kl Muta-
tions W e have previously demonstrated that synthetic pep tides 
corresponding in amino acid sequence to three principal overlap 
regions ofK1/KlO KIF can be used to disassemble preformed KIF ill 
vitro [24,25], presumably due to competition with the similar se-
quence on the chains in th e intact KIF. These regions are the Hl end 
domain, lA, and end of 2B rod domain sequences. Peptides from 
other portions of the keratin chains or unrelated proteins do not 
promote disassembly [24,25] . 
Interestingly, the three new mutations described here for Kl lie 
within these sequences, and so synthetic peptides bearing the result-
ing substitutions were tested using turbidity to monitor the degree 
of KIF structural change (Table I). The fu ll-length wildtype H1 
peptide promoted massive disassembly of preformed human Kl/ 
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Figure 3. A serine to proline mutation in fami ly 3138. A) Pedigree of 
simplex family. B) Portion of a sequencing gel of the affected person (II-l) 
(left set of lalles) and unaffected father 1-1 (right set of larres). The gel of the 
unaffected mother 1-2 was the same as 1-1. The patient 11-1 shows an addi-
tional band in the C position in one allele resulting in the substitution of a 
proline for serine res idue. C) A PASA assay using primers specific for either 
the normal Kl gene sequence (a 3' T), or the mutant sequence (a 3' C), were 
used to test for the presence of the Illutation. DNA from the affected child 
II-I yields an amplified band of 433 bp with both the mutant (M) and 
wildtype (WT) primers. However, only the wildtype primers ampli fy the 
DNA from the unaffected parents, 1-1 and 1-2. Markers are Hae III digestion 
of<l>X 174 DNA (Gibco-BRL). 
Kl0 to subfilamentous particles containing only one to four mole-
cules w ithin 90 min [1 2,25]. However, the peptide bearing the 
Vl1 G amino acid substitution seen in fami ly 1027 was much less 
effective; electron microscopy revealed (data not shown) that the 
slight decrease in turbidity (Table I, lille 2) was due to reductions in 
KIF length from > 2 to 0.5 -1 fJ.m. Even after 6 h , the KIF were sti ll 
largely intact. The fu ll-length wildtype lA peptide also promoted 
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complete disassemb ly of preformed KIF to subfilamentous particles, 
generally only one molecule in size [25] . This property is retained 
within the sequence of the first 18 residues rather than the second 
18 (Table I, compare line 4 with lilies 3 and 5) as peptide 5 containing 
residues 18 - 35 of the Kl chain had on ly a minor effect on KIF 
length. Notably, peptides bearing the N8S substitution of family 
1002 or the S 13P substitution offamily 3138 (Table1, lines 6, 7) only 
shortened KIF, and did not promote massive disassembly, even af-
ter 6 h. 
These data show that the three substituted peptides do not func-
tion like the wildtype peptides presumably because their structures 
have been altered. Because of their altered structures they are unable 
to effectively compete with the native sequences in the KIF in the 
same way as the wildtype peptides. By extension, we infer th at the 
ful l-length mutant K1 chains are unable to function normally in the 
KIF ill IJivo because of altered structure, promoting the pathology 
ofEH. 
DISCUSSION 
This laboratory has initiated a major project to identify the likely 
disease-causing mutation in a coll ection ofEH cases for the purpose 
of building a "cata log" with two major purposes in mind . First, if it 
turns out that the mutations are clustered in specific sequence re-
gions of the keratin chains, such data would make further character-
ization of mutations for this disease far easier and systematic because 
workers will then know where to focus attention in the future. 
Thus prospects for genetic counseling and prenatal diagnos is are 
likely to be enhanced. Second, the occurrence of the mutations in 
the keratin chains may provide important clues to the structure of 
KIF and their dynamic functions in cells. An important spinoff of 
such models may be improved therapeutic interventions, manage-
ment, or even cure of the disease. 
Mutations in Keratins Causing EH Are Clustered In this 
paper, we report three new mutations for EH that occur in the K1 
chain. These occur only in affected patients and not in unaffected 
family members. We have described strategies for the analysis and 
sequencing of amplified DNA of patients, and tests to ensure that 
they are the likely causative mutation, not merely rare sequence 
polymorphisms within the normal human population. Each of the 
amino acid substitutions occurs in highly conserved sequence re-
gions of the H1 and lA domains encoded by exon 1 of the K1 gene. 
In addition we have reported one other mutation position in the 
Kl gene in the HI domain of exon 1 sequences [1 2J. We know of 
two other mutations in the K1 chain ([16], W .H .I. McLean, per-
sonal communication) . In other studies we have also identified the 
mutations in the K10 chain in a total of eight other families, repre-
senting five amino acid 5llbstitutions; that is, we have found muta-
tions in either the K1 or K10 chain in 12 of 19 families . Together 
Table I. 
Peptide 
Number 
1 
2 
3 
4 
5 
6 
7 
Disassembly of Preformed KIF by Synthetic Peptides' 
Experiment 
KIF alone 
Wildtype Kl Hl 
Mutant K1 H1 VIIG 
Wild type full- length Kl lA 
Wildtype Kl lA residues 1-18 
Wildtype Kl lA residues 18-35 
Mutant Kl lA residues 1-18 N8S 
Mutant K 1 lA residues 1-18 S 13P 
Light Scattering 
Remaining (%) 
100 
0±2 
77±3 
7± 1 
3± 1 
81 ± 1 
74 ± 1 
77 ± 0 
• The data are expressed as the percent oflight scattering remaining after 60 min and 
are the average ± SO of two or three measurements on one batch of human K 1 / K 1 0 
KIF. We have used electron microscopy to assess these chan ges [12,24]. For example, 
0% means the KIF have becn totally disassembled to subfilamentous particles and no 
longer scatter light. whereas 77% means the KIF arc still largely intact with minor 
shortcning and/or unravcling. Wildeype peptides were designed from the published K 1 
sequellce [1 9,23). The thrce mutant pep tides were designed bascd on the identified 
substitutions see n in th e K 1 chain in the three families studied here. 
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Table II. Locations of Known Mutations in EHa 
Keratin Number 
Domain Mutation Chain Reference of Families 
HI VIIG KI Present work 
HI L17P KI [12] 
lA S6P K1 [16] 1 
IA N8S K1 Present work 1 
lA N8H K1D [28J 2 
lA RIDH KID [14,15,28j.b 5 
1A R1DC K1D [28] 2 
IA S13P K1 Presen t work I 
1A Y14D K1D [28) 1 
1A Ll5S K1D [15] 1 
2B LlD3Q K1D [28] 1 
2B EI18Q K1 [15) 1 
, Sequence designations are single amino acid code letter for the wild type residue-
residue position number-amino acid substituted in the mutation, so that VllG repre-
sents a valine to glycine substitution in the I I th residue position [30- 32] of the HI 
subdomain. 
, J-M Yang et ai, unpublished data. 
with existing published data [12-15]' this means there are now 10 
known different amino acid positions that are changed in the Kl or 
KI0 chains in EH, from a total of 18 separate families reported 
(Table II) . Compilation of these data (Table II) reveals a non-ran-
dom distribution of mutations: two (11 %) occur in HI, 14 (78%) 
(six positions) occur in the first half of the 1A rod domain sequences, 
and two (11 %) occur in sequences at the end of the 2B rod domain. 
Accordingly, we can speculate that most mutations in EH patients 
will be discovered following the amplification of only the first exon 
of the keratin chains, as described here for K1. Because 14 of 18 
mutations occur in the first 15 residues of the lA rod domain, this 
region may constitute a "hot window" of increased mutational 
sensitivity in EH. Furthermore, mutations in the RIO position of 
K 10 represent nearly half of all the cases ofEH described so far. That 
is, this may represent a "hot spot" for mutations in EH [4-6]. 
Interestingly, this same position has been described as a hot spot for 
mutations in the K14 gene in EBS [4-6,29] . However, we and 
others may have ascertained a biased set of EH patients who were 
likely referred to research protocols and whose disease presentation 
may not be representative of the full spectrum of EH patients . Nev-
ertheless, the present insights should aid greatly the future identifi-
cation of mutations in the keratin genes causing these genoderma-
toses. 
Most Mutations Occur in Critical Overlap Regions of the 
Keratin Chains Recent studies have suggested advanced two-
dimensional models for K1/K10 KIF structure [25] that are of rele-
vance for mutations in EH. Cross-linking analyses showed there are 
three principal modes by which a pair of antiparallel molecules may 
be aligned in the KIF, and have provided estimates of the axial 
dimensions of these modes: All' in which the two molecu les are 
staggered by about 16 nm so that their 1B rod domain segments are 
overlapped; A22 , in which the two molecules are staggered by about 
28 nm so that their segments 2B are overlapped; and A12 , in which 
the two molecules are aligned in register (staggered by about 1 nm) . 
Several cross-links established that the axial repeat length (45 nm) 
of molecules in a KIF is demonstrably less than the length of each 
molecule (46 nm). Thus these data permitted identification of a 
fourth mode of alignment, termed ACN , in which about the last 
1 nm of the 2B rod domain segment of one molecule overlaps with 
the first 1 nm of the lA rod domain segment of a similarly directed 
molecule. This corresponds to a nominal overlap of about 10 amino 
acids of the lA and 2B sequences. This means that the sequence 
regions H1, beginning of lA, end of 2B and H2 all lie very close to 
and/or overlap each other within a KIF. Furthermore, we [24] have 
suggested that the H1 (and possibly H2) subdomaills, immediately 
adjacent to the beginning and end of the rod domain, are involved in 
the alignment of nearest neighbor molecules in KIF, perhaps by 
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ionic interactions of basic residues in H 1 with the canonical acidic 
residues of the end of the 2B rod domain segment. In the All and A22 
alignment modes, these sequence regions also overlap with the 
middle of the rod domain, near the L2 segment. These structural 
principles may explain why these five regions represent the most 
highly conserved sequences throughout the family of keratin and 
other IF chains [30 - 32]. 
Interestingly, all 12 substitutions known so far for EH occur in or 
near these conserved overlap sequence regions. Of the 12 substitu-
tions, six lie within the nominal 10 residue 1A-2B ACN overlap 
window; three others lie just outside the window; and two occur in 
H1. No mutations have been observed yet in H2 or L2 sequences. 
However, little is yet known about how the molecules fold in 
three dimensions to form the intact KIF. It appears that inappropri-
ate amino acid substitutions in either of the HI, lA, or 2B sequences 
that participate in the ACN overlap are the most critical for KIF 
structure and function. Presumably key ionic, van der Waals and/or 
H -bonds are prevented (or introduced) that markedly affect molec-
ular packing, stability, and thus KIF dynamics in the living epithe-
lial cells [5 ,6]. Apparently, mutations lying in residue positions just 
outside of the overlap window interfere with KIF structure as much 
as those within the window, so that amino acids that should align or 
interact in three dimensions are unable to do so. Further structural 
studies are in progress to address these questions . 
Other Mutations in EH This laboratory has been unable to find 
mutations in the rod domain sequences of the K1 or K10 chains in 
seven of 19 (37%) probands of EH. Further work will be necessary 
to determine whether such mutations reside in the V1 or highly 
variable V2 end domain sequences, other keratin genes expressed in 
the epidermis such as K2e and K9, or even in other genes coex-
pressed in terminally differentiating epidermis. 
Is There a Correlation Between Disease Presentation and 
Mutation in EH? We note that the clinical presentations of the 
family members of four cases reported here and previously [12] 
involving the K1 chain all display severe palmar-plantar (palm and 
sole) hyperkeratosis. In contrast, truncal involvement is pronounced 
whereas seVere palmar-plantar hyperkeratosis is absent in those 
families with KlO mutations (JJ. DiGiovanna and S.]. Bale, sub-
mitted). This observation raises the intriguing question as to 
whether it may be possible in the future to predict the nature and 
location of the causative mutation based UPO? the clinical presenta-
tion of the disease. Analyses of many addItIonal cases of EH may 
establish whether this association is valid. 
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NEWS RELEASE 
In 1994, the Certifying Examination of the American Board of Dermatology wi ll be held at the 
Holiday Inn O'Hare Airport in Rosemont, Illinois on October 9 and 10, 1994. The deadline for 
receipt of applications is May 1, 1994. 
The next Dermatopathology Special Qualification Examination will be held in Chicago, 
Illinois on October 20, 1995. The deadline for receipt of applications is July 1, 1995. 
The next Examination for Special Qualification in Dermatological Immunology/Diagnostic 
and Laboratory Immunology will be held in Rosemont, Illinois on October 20, 1995. The 
deadline for receipt of applications is April 1, 1995. 
For further information on these examinations, please contact: Harry J. Hurley, M.D., 
Executive Director, American Board of Dermatology, Henry Ford Hospita l, Detroit, MI 
48202. 
